Pediatric Cannabis Poisoning Calls Rose 3,307% in 25 Years, National Data Show
Pediatric cannabis poisoning cases reported to U.S. poison centers rose 3,307 percent between 2000 and 2024, according to a new 25-year national analysis. Cannabinoids, mostly edible products, accounted for 84.7 percent of the 41,612 unintentional…
Cannabis Legalization Outcomes: What 329 Studies Found
Cannabis legalization outcomes across 329 studies included fewer possession arrests and generally more adult access and use. Youth prevalence did not rise uniformly, but pediatric exposure and acute-care signals remained important. Market and road-safety…
CBD Oil and Autism: What a New Randomized Trial Shows About Social Cognition
CBD oil autism social cognition: A post hoc subanalysis of a randomized, placebo-controlled trial examined CBD-rich cannabis oil's effect on facial expression recognition and theory of mind in 19 children with autism spectrum disorder. Within-group…
THC/CBD Oil for Dementia Agitation: What the MedCanDem Trial Found
THC CBD oil dementia agitation: The MedCanDem trial, a randomized, placebo-controlled crossover study in 25 nursing home residents with severe dementia, found no significant reduction in agitation on the CMAI scale. The oil significantly lowered…
Cannabis Use Disorder Is Rising Among US Adults
Cannabis use disorder increased among US adult males and females from 2021 through 2024. The national survey also found growth in moderate-to-severe disorder across several age groups. The findings support routine screening but do not identify a cause or…
Social Media Apps and Youth Cannabis Use: What the ABCD Study Found
App-specific social media use adolescent cannabis: The ABCD Study reveals that app-specific social media use, particularly Instagram time, is associated with adolescent cannabis use. This observational research highlights how different platforms relate…
GLP-1 Drugs and Cervical Fusion: What Conflicting Real-World Evidence Shows
GLP-1 cervical fusion outcomes were synthesized across 12 retrospective cohorts. Estimates differed by procedure and dataset, and the overall model showed extreme heterogeneity. The evidence does not establish a protective or harmful class-wide effect.
Anxiety and Depression, Not Substance Use, Tracked With Symptom Severity in a New Early Schizophrenia Study
A new early schizophrenia anxiety depression study of 170 patients in Northern India found that anxiety and depression significantly correlated with symptom severity. Substance use, including cannabis, tobacco, alcohol, and opioids, did not show a strong…
Cannabinoids for Mental Health and Addiction: What 200 Studies Actually Show
Cannabinoids for mental health were examined across 200 randomized and observational studies. Anxiety and PTSD signals were limited by low certainty, indirectness, and heterogeneity, while depression showed no evident benefit. THC increased withdrawals…
Fenfluramine for Dravet Syndrome: What a New Pooled Analysis Means for Clinicians Also Using CBD
This fenfluramine dravet syndrome stratified analysis pools data from three phase 3 trials, demonstrating seizure reduction across most patient subgroups. The study highlights fenfluramine's safety profile and efficacy, providing key insights for…